Exploring Metabolic Abnormalities of Amino Acids in Preeclampsia-Associated Cardiac Physiological Dysfunction via Cardiomyocyte-Based Multimodal Biosensing

Preeclampsia (PE) is a life-threatening hypertensive disorder of pregnancy that leads to high incidence and severe maternal-fetal cardiovascular risks. Conventional clinical examination and investigation methodologies make it difficult to reveal the PE-induced potential cardiac physiology dysfunction at the cellular level in the early stage. To overcome the limitations of these methods, we developed an integrated electrical and optical dynamic cardiomyocyte-based physiology (CBP) biosensing platform for PE-associated cardiovascular disease. Using this platform, we demonstrated that plasma from PE patients causes acute electrophysiological and calcium-handling abnormalities in cardiomyocytes, and the metabolomic analysis of plasma indicates a significant elevation of glycine and serine levels, which are verified as key contributors to myocardial dysfunction. Furthermore, the coenzyme Q10 intervention can effectively relieve cardiac physiology dysfunction by monitoring the cardiomyocytes continuously and dynamically. Our study establishes a high-content sensitive CBP biosensing platform to precisely diagnose and treat PE-induced myocardial injury. This utility strategy offers a powerful tool to promote PE-associated cardiological research and has great potential to improve the limitations of existing clinical studies.